View in EDS

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.

Saved in:
Bibliographic Details
Title: Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.
Authors: Gray GE; Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa; South African Medical Research Council, Cape Town, South Africa. Electronic address: gray@pixie.co.za., Moodie Z; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Metch B; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Bekker LG; Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa., Churchyard G; Aurum Institute for Health Research, Johannesburg, South Africa., Nchabeleng M; MEDUNSA HIV Clinical Research Unit, University of Limpopo, Mankweng-E, South Africa., Mlisana K; Centre for AIDS Programme for Research in South Africa, University of KwaZulu-Natal, Durban, South Africa., Laher F; Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Roux S; Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa., Mngadi K; Centre for AIDS Programme for Research in South Africa, University of KwaZulu-Natal, Durban, South Africa., Innes C; Aurum Institute for Health Research, Johannesburg, South Africa., Mathebula M; MEDUNSA HIV Clinical Research Unit, University of Limpopo, Mankweng-E, South Africa., Allen M; Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Robertson M; Infectious Diseases and Vaccines Clinical Research, Merck and Company, North Wales, PA, USA., Kublin J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Corporate Authors: HVTN 503/Phambili study team
Source: The Lancet. Infectious diseases [Lancet Infect Dis] 2014 May; Vol. 14 (5), pp. 388-96. Date of Electronic Publication: 2014 Feb 20.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Science Country of Publication: United States NLM ID: 101130150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4457 (Electronic) Linking ISSN: 14733099 NLM ISO Abbreviation: Lancet Infect Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 24560541
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Gray+GE%22">Gray GE</searchLink>; Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa; South African Medical Research Council, Cape Town, South Africa. Electronic address: gray@pixie.co.za.<br /><searchLink fieldCode="AU" term="%22Moodie+Z%22">Moodie Z</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Metch+B%22">Metch B</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Gilbert+PB%22">Gilbert PB</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Bekker+LG%22">Bekker LG</searchLink>; Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa.<br /><searchLink fieldCode="AU" term="%22Churchyard+G%22">Churchyard G</searchLink>; Aurum Institute for Health Research, Johannesburg, South Africa.<br /><searchLink fieldCode="AU" term="%22Nchabeleng+M%22">Nchabeleng M</searchLink>; MEDUNSA HIV Clinical Research Unit, University of Limpopo, Mankweng-E, South Africa.<br /><searchLink fieldCode="AU" term="%22Mlisana+K%22">Mlisana K</searchLink>; Centre for AIDS Programme for Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.<br /><searchLink fieldCode="AU" term="%22Laher+F%22">Laher F</searchLink>; Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.<br /><searchLink fieldCode="AU" term="%22Roux+S%22">Roux S</searchLink>; Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa.<br /><searchLink fieldCode="AU" term="%22Mngadi+K%22">Mngadi K</searchLink>; Centre for AIDS Programme for Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.<br /><searchLink fieldCode="AU" term="%22Innes+C%22">Innes C</searchLink>; Aurum Institute for Health Research, Johannesburg, South Africa.<br /><searchLink fieldCode="AU" term="%22Mathebula+M%22">Mathebula M</searchLink>; MEDUNSA HIV Clinical Research Unit, University of Limpopo, Mankweng-E, South Africa.<br /><searchLink fieldCode="AU" term="%22Allen+M%22">Allen M</searchLink>; Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22McElrath+MJ%22">McElrath MJ</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Robertson+M%22">Robertson M</searchLink>; Infectious Diseases and Vaccines Clinical Research, Merck and Company, North Wales, PA, USA.<br /><searchLink fieldCode="AU" term="%22Kublin+J%22">Kublin J</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.<br /><searchLink fieldCode="AU" term="%22Corey+L%22">Corey L</searchLink>; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22HVTN+503%2FPhambili+study+team%22">HVTN 503/Phambili study team</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101130150%22">The Lancet. Infectious diseases</searchLink> [Lancet Infect Dis] 2014 May; Vol. 14 (5), pp. 388-96. <i>Date of Electronic Publication: </i>2014 Feb 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science%22">Elsevier Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101130150 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-4457 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214733099%22">14733099 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Infect Dis <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=24560541
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1473-3099(14)70020-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 388
    Titles:
      – TitleFull: Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Gray GE
      – PersonEntity:
          Name:
            NameFull: Moodie Z
      – PersonEntity:
          Name:
            NameFull: Metch B
      – PersonEntity:
          Name:
            NameFull: Gilbert PB
      – PersonEntity:
          Name:
            NameFull: Bekker LG
      – PersonEntity:
          Name:
            NameFull: Churchyard G
      – PersonEntity:
          Name:
            NameFull: Nchabeleng M
      – PersonEntity:
          Name:
            NameFull: Mlisana K
      – PersonEntity:
          Name:
            NameFull: Laher F
      – PersonEntity:
          Name:
            NameFull: Roux S
      – PersonEntity:
          Name:
            NameFull: Mngadi K
      – PersonEntity:
          Name:
            NameFull: Innes C
      – PersonEntity:
          Name:
            NameFull: Mathebula M
      – PersonEntity:
          Name:
            NameFull: Allen M
      – PersonEntity:
          Name:
            NameFull: McElrath MJ
      – PersonEntity:
          Name:
            NameFull: Robertson M
      – PersonEntity:
          Name:
            NameFull: Kublin J
      – PersonEntity:
          Name:
            NameFull: Corey L
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2014 May
              Type: published
              Y: 2014
          Identifiers:
            – Type: issn-electronic
              Value: 1474-4457
          Numbering:
            – Type: volume
              Value: 14
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: The Lancet. Infectious diseases
              Type: main
ResultId 1